Q-omics provides the consensus-scored PIK3IP1-DT profile across patient tissues and cancer cell-line models. PIK3IP1-DT expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PIK3IP1-DT is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PIK3IP1-DT RNA expression shows 16,889 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUSC, BLCA, and UVM as cancer lineages where PIK3IP1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIK3IP1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIK3IP1-DT survival associations across molecular data types. PIK3IP1-DT RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIK3IP1-DT RNA expression–survival associations across cancer types. High PIK3IP1-DT expression shows unfavorable associations in KIRC and COAD, but favorable associations in LUSC, BLCA, READ and PAAD. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for PIK3IP1-DT RNA expression.
This table summarizes PIK3IP1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PIK3IP1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIK3IP1-DT shows higher tumor expression in BLCA, KIRC, COAD, CHOL, KICH and LIHC. The BLCA box plot shows higher PIK3IP1-DT RNA expression in tumor versus normal tissue (log2 FC = +0.639, t-test p < 0.001).
This table shows molecular features associated with PIK3IP1-DT in patient tissues and cancer cell lines. In patient samples, PIK3IP1-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
